SpyGlass Pharma Completes Enrollment in Phase I/II Study of its Promising Long-Term Drug Delivery Platform for Glaucoma and Ocular Hypertension
19. November 2024 08:00 ET
|
SpyGlass Pharma, Inc.
SpyGlass prepares for End of Phase II meeting with the FDA to advance its Drug Delivery Platform into Phase III pivotal studiesInnovative platform has the potential to enable all cataract surgeons to...
SpyGlass Pharma Presents Promising 18-month Data of its Innovative Drug Delivery Platform Implanted During Routine Cataract Surgery in Eyes with Glaucoma
17. Oktober 2024 14:35 ET
|
SpyGlass Pharma, Inc.
Mean intraocular pressure (IOP) was reduced by 43.7% from baseline at month 18All patients remained off topical IOP-lowering medications and achieved >20% IOP reductionAll eyes achieved Visual...
SpyGlass Pharma Unveils Compelling 1-Year Data of Its Innovative Drug Delivery Platform Implanted During Routine Cataract Surgery in Eyes with Glaucoma
02. April 2024 08:00 ET
|
SpyGlass Pharma, Inc.
Share Mean intraocular pressure (IOP) reduction from washed-out baseline was 44.6% at Month 12; all patients had IOP reduction >20% and IOP ≤ 18 mmHg. 100% of patients remained off topical...
SpyGlass Pharma Strengthens Leadership to Further Advance its Intraocular Drug Delivery Platform
05. Dezember 2023 09:00 ET
|
SpyGlass Pharma, Inc.
Margot Goodkin, M.D., Ph.D., appointed Chief Medical OfficerBilal Khan, MBA, CEO of New World Medical, appointed to the SpyGlass Board of Directors ALISO VIEJO, Calif., Dec. 05, 2023 (GLOBE...
SpyGlass Pharma Initiates Phase I/II Clinical Trial of its Intraocular Drug Delivery Platform
31. Oktober 2023 07:00 ET
|
SpyGlass Pharma, Inc.
ALISO VIEJO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, announced today the initiation of a Phase I/II clinical trial...
SpyGlass Pharma Unveils 6-Month Data from the First-In-Human Trial of Its Innovative Drug Delivery Platform for Chronic Eye Conditions
03. Februar 2023 11:15 ET
|
SpyGlass Pharma, Inc.
ALISO VIEJO, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a privately held ophthalmic therapeutics company, released 6-month data from a First-in-Human glaucoma treatment trial showing...
SpyGlass Pharma Presents Compelling 3-Month Data from the First-In-Human Trial of Its Innovative Drug Delivery Platform for Chronic Eye Conditions
29. September 2022 15:15 ET
|
Spyglass Pharma, Inc.
ALISO VIEJO, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a privately held ophthalmic therapeutics company, today announced 3-month data from a First-in-Human glaucoma treatment trial...